---
document_datetime: 2024-12-18 17:56:40
document_pages: 41
document_pathfilename: www.ema.europa.eu/en/documents/procedural-steps-after/gilenya-epar-procedural-steps-taken-scientific-information-after-authorisation-archive_en.pdf
document_name: gilenya-epar-procedural-steps-taken-scientific-information-after-authorisation-archive_en.pdf
version: success
processing_time: 25.3696943
conversion_datetime: 2025-12-29 21:26:23.397837
docling_version:
  docling-serve: 1.9.0
  docling-jobkit: 1.8.0
  docling: 2.66.0
  docling-core: 2.57.0
  docling-ibm-models: 3.10.3
  docling-parse: 4.7.2
  python: cpython-313 (3.13.11)
  plaform: macOS-26.2-arm64-arm-64bit-Mach-O
---
## Gilenya

Procedural steps taken and scientific information after the authorisation

| Application number   | Scope                                                                                                                                                                                                                 | Opinion/ Notification 1 issued on   | Commission Decision Issued 2 / amended on   | Product Information affected 3   | Summary                                                                                                                                                                                                                                                                           |
|----------------------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-------------------------------------|---------------------------------------------|----------------------------------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| II/0090/G            | This was an application for a group of variations. Grouped application comprising two variations as follows: Type II (C.I.3.b) - Update of section 4.3 of the SmPC in order to add suspected or confirmed progressive | 14/11/2024                          | 16/12/2024                                  | SmPC, Annex II and PL            | The product information is updated to add suspected or confirmed PML as a contraindication, to add IRIS as an ADR with frequency not known and to amend a warning on PML and add a warning on IRIS. For more information, please refer to the Summary of Product Characteristics. |

<!-- image -->

<!-- image -->

<div style=\"page-break-after: always\"></div>

|           | multifocal leukoencephalopathy (PML) as a new contraindication; update of section 4.4 of the SmPC to amend an existing warning on PML and to add a new warning on immune reconstitution inflammatory syndrome (IRIS) and update of section 4.8 of the SmPC in order to add IRIS as ADR with frequency not know. The educational materials are updated on information about IRIS and also updated to improve the general readability and better address key messages and recommendations for healthcare professionals and for patients following the assessment of procedure PSUSA/00001393/202302. The Package Leaflet and Annex II are updated accordingly. The RMP version 20.2 has also been agreed. Type IA (A.6) - To change the ATC Code of Fingolimod from L04AA27 to L04AE01. C.I.3.b - Change(s) in the SPC, Labelling or PL intended to implement the outcome of a procedure concerning PSUR or PASS or the outcome of the assessment done under A 45/46 - Change(s) with new additional data submitted by the MAH A.6 - Administrative change - Change in ATC   |            |     |
|-----------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|-----|
| IA/0096/G | This was an application for a group of variations. B.I.a.1.f - Change in the manufacturer of AS or of a starting material/reagent/intermediate for AS - Changes to quality control testing arrangements for the AS -replacement or addition of a site where                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                | 15/11/2024 | n/a |

<div style=\"page-break-after: always\"></div>

|             | takes place B.I.a.1.f - Change in the manufacturer of AS or of a starting material/reagent/intermediate for AS - Changes to quality control testing arrangements for the AS -replacement or addition of a site where batch control/testing takes place B.I.a.1.f - Change in the manufacturer of AS or of a starting material/reagent/intermediate for AS - Changes to quality control testing arrangements for the AS -replacement or addition of a site where batch control/testing takes place                                                                                                                                                                                                                                                                           |            |            |                 | batch control/testing   |
|-------------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|------------|-----------------|-------------------------|
| IAIN/0097/G | This was an application for a group of variations. B.II.b.2.c.1 - Change to importer, batch release arrangements and quality control testing of the FP - Replacement or addition of a manufacturer responsible for importation and/or batch release - Not including batch control/testing A.7 - Administrative change - Deletion of manufacturing sites A.7 - Administrative change - Deletion of manufacturing sites A.7 - Administrative change - Deletion of manufacturing sites B.II.b.2.c.1 - Change to importer, batch release arrangements and quality control testing of the FP - Replacement or addition of a manufacturer responsible for importation and/or batch release - Not including batch control/testing B.II.b.2.c.1 - Change to importer, batch release | 14/11/2024 | 16/12/2024 | Annex II and PL | arrangements and        |

<div style=\"page-break-after: always\"></div>

|           | Replacement or addition of a manufacturer responsible for importation and/or batch release - Not including batch control/testing                                                                                                                                                                                                                                                                                                                                                                                                                                                                                         |            |     |
|-----------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|-----|
| IA/0095/G | This was an application for a group of variations. B.III.1.b.2 - Submission of a new/updated or deletion of Ph. Eur. TSE Certificate of Suitability - New certificate for a starting material/reagent/intermediate/or excipient from a new or an already approved manufacturer B.III.1.b.4 - Submission of a new/updated or deletion of Ph. Eur. TSE Certificate of Suitability - Deletion of certificates (in case multiple certificates exist per material) B.III.1.b.4 - Submission of a new/updated or deletion of Ph. Eur. TSE Certificate of Suitability - Deletion of certificates (in case multiple certificates | 19/06/2024 | n/a |
| IA/0094/G | This was an application for a group of variations. A.7 - Administrative change - Deletion of manufacturing sites A.7 - Administrative change - Deletion of manufacturing sites A.7 - Administrative change - Deletion of manufacturing sites A.7 - Administrative change - Deletion of manufacturing sites A.7 - Administrative change - Deletion of                                                                                                                                                                                                                                                                     | 14/06/2024 | n/a |

<div style=\"page-break-after: always\"></div>

| IA/0093/G          | This was an application for a group of variations. A.7 - Administrative change - Deletion of manufacturing sites A.7 - Administrative change - Deletion of manufacturing sites                            | 14/06/2024   | n/a   |                                   |
|--------------------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|--------------|-------|-----------------------------------|
| IAIN/0091          | B.II.b.1.a - Replacement or addition of a manufacturing site for the FP - Secondary packaging site                                                                                                        | 04/04/2024   | n/a   |                                   |
| IAIN/0089          | B.II.b.1.a - Replacement or addition of a manufacturing site for the FP - Secondary packaging site                                                                                                        | 04/04/2024   | n/a   |                                   |
| IA/0087            | B.II.b.5.a - Change to in-process tests or limits applied during the manufacture of the finished product - Tightening of in-process limits                                                                | 19/02/2024   | n/a   |                                   |
| IB/0086            | B.II.d.1.z - Change in the specification parameters and/or limits of the finished product - Other variation                                                                                               | 09/11/2023   | n/a   |                                   |
| PSUSA/1393/ 202302 | Periodic Safety Update EU Single assessment - fingolimod                                                                                                                                                  | 26/10/2023   | n/a   | PRAC Recommendation - maintenance |
| IA/0085/G          | This was an application for a group of variations. B.I.b.1.b - Change in the specification parameters and/or limits of an AS, starting material/intermediate/reagent - Tightening of specification limits | 26/09/2023   | n/a   |                                   |

<div style=\"page-break-after: always\"></div>

|             | in test procedure for AS or starting material/reagent/intermediate - Minor changes to an approved test procedure B.I.b.1.b - Change in the specification parameters and/or limits of an AS, starting material/intermediate/reagent - Tightening of specification limits B.I.b.1.c - Change in the specification parameters and/or limits of an AS, starting material/intermediate/reagent - Addition of a new specification parameter to the specification with its test method            |            |            |                              | B.I.b.2.a - Change corresponding   |
|-------------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|------------|------------------------------|------------------------------------|
| IAIN/0084/G | This was an application for a group of variations. A.5.b - Administrative change - Change in the name and/or address of a manufacturer/importer of the finished product, including quality control sites (excluding manufacturer for batch release) B.II.b.2.c.1 - Change to importer, batch release arrangements and quality control testing of the FP - Replacement or addition of a manufacturer responsible for importation and/or batch release - Not including batch control/testing | 14/09/2023 | 19/04/2024 | Annex II and PL              |                                    |
| IB/0081/G   | This was an application for a group of variations. B.II.e.2.b - Change in the specification parameters and/or limits of the immediate packaging of the finished product - Addition of a new specification parameter to the specification with its corresponding test method                                                                                                                                                                                                                | 09/05/2023 | 19/04/2024 | SmPC, Annex II and Labelling |                                    |

<div style=\"page-break-after: always\"></div>

<!-- image -->

| B.III.1.b.2 - Submission deletion of Ph. Eur. TSE New certificate for a starting material/reagent/intermediate/or new or an already approved B.II.e.2.b - Change in and/or limits of the immediate finished product - Addition parameter to the specification test method B.II.e.4.a - Change in container or closure (immediate sterile medicinal products B.III.1.b.2 - Submission deletion of Ph. Eur. TSE New certificate for a starting material/reagent/intermediate/or new or an already approved B.III.1.b.2 - Submission deletion of Ph. Eur. TSE New certificate for a starting material/reagent/intermediate/or new or an already approved B.III.1.b.2 - Submission deletion of Ph. Eur. TSE New certificate for a starting material/reagent/intermediate/or new or an already approved B.II.b.1.a - Replacement manufacturing site for   | site   |
|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|--------|

<div style=\"page-break-after: always\"></div>

| deletion of Ph. Eur. TSE New certificate for a starting material/reagent/intermediate/or new or an already approved B.II.e.2.b - Change in and/or limits of the immediate finished product - Addition parameter to the specification test method B.II.b.1.e - Replacement manufacturing site for manufacturing operation(s) release, batch control, packaging, for non-sterile B.II.b.1.b - Replacement manufacturing site for site B.III.1.b.2 - Submission deletion of Ph. Eur. TSE New certificate for a starting material/reagent/intermediate/or new or an already approved B.II.a.z - Change in description the Finished Product - B.II.a.1.a - Change or or other markings including of inks used for product imprints, bossing or other B.III.1.b.2 - Submission deletion of Ph. Eur. TSE New certificate for a starting   |
|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

<div style=\"page-break-after: always\"></div>

|           | B.III.1.b.2 - Submission of a new/updated or deletion of Ph. Eur. TSE Certificate of Suitability - New certificate for a starting material/reagent/intermediate/or excipient from a new or an already approved manufacturer B.II.b.2.c.2 - Change to importer, batch release arrangements and quality control testing of the FP - Including batch control/testing B.II.e.2.a - Change in the specification parameters and/or limits of the immediate packaging of the finished product - Tightening of specification limits   |            |            |                        | new or an already approved   |
|-----------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|------------|------------------------|------------------------------|
| IAIN/0082 | B.II.b.1.a - Replacement or addition of a manufacturing site for the FP - Secondary packaging site                                                                                                                                                                                                                                                                                                                                                                                                                            | 27/02/2023 | n/a        |                        |                              |
| IA/0080   | B.II.e.4.a - Change in shape or dimensions of the container or closure (immediate packaging) - Non- sterile medicinal products                                                                                                                                                                                                                                                                                                                                                                                                | 02/12/2022 | 23/02/2023 | SmPC, Labelling and PL |                              |
| IA/0079   | A.7 - Administrative change - Deletion of manufacturing sites                                                                                                                                                                                                                                                                                                                                                                                                                                                                 | 03/10/2022 | n/a        |                        |                              |
| IA/0078   | B.II.b.2.a - Change to importer, batch release arrangements and quality control testing of the FP - Replacement/addition of a site where batch control/testing takes place                                                                                                                                                                                                                                                                                                                                                    | 01/08/2022 | n/a        |                        |                              |
| IB/0077/G | This was an application for a group of variations. B.II.b.4.b - Change in the batch size (including batch                                                                                                                                                                                                                                                                                                                                                                                                                     | 29/07/2022 | 23/02/2023 | Annex II and PL        |                              |

<div style=\"page-break-after: always\"></div>

| size ranges) of the finished down to 10-fold B.III.1.b.2 - Submission deletion of Ph. Eur. TSE New certificate for a starting material/reagent/intermediate/or new or an already approved B.II.e.2.b - Change in and/or limits of the immediate finished product - Addition parameter to the specification test method B.II.b.1.e - Replacement manufacturing site for manufacturing operation(s) release, batch control, packaging, for non-sterile B.III.1.b.2 - Submission deletion of Ph. Eur. TSE New certificate for a starting material/reagent/intermediate/or new or an already approved B.II.b.5.b - Change to applied during the manufacture product - Addition of a B.III.1.b.2 - Submission deletion of Ph. Eur. TSE New certificate for a starting material/reagent/intermediate/or new or an already approved B.II.e.2.b - Change in   |
|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

<div style=\"page-break-after: always\"></div>

<!-- image -->

| finished product - Addition parameter to the specification test method B.II.e.2.b - Change in the and/or limits of the immediate finished product - Addition parameter to the specification test method B.III.1.b.2 - Submission deletion of Ph. Eur. TSE New certificate for a starting material/reagent/intermediate/or new or an already approved B.II.b.3.a - Change in the the finished or intermediate in the manufacturing process B.II.b.3.a - Change in the the finished or intermediate in the manufacturing process B.III.1.b.2 - Submission deletion of Ph. Eur. TSE New certificate for a starting material/reagent/intermediate/or new or an already approved B.III.1.b.2 - Submission deletion of Ph. Eur. TSE New certificate for a starting material/reagent/intermediate/or new or an already approved B.II.b.2.a - Change to importer, arrangements and quality   |
|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

<div style=\"page-break-after: always\"></div>

| control/testing takes B.III.1.b.2 - Submission deletion of Ph. Eur. New certificate for a material/reagent/intermediate/or new or an already approved B.III.1.b.2 - Submission deletion of Ph. Eur. New certificate for a material/reagent/intermediate/or new or an already approved B.III.1.b.2 - Submission deletion of Ph. Eur. New certificate for a material/reagent/intermediate/or new or an already approved B.III.1.b.2 - Submission deletion of Ph. Eur. New certificate for a material/reagent/intermediate/or new or an already approved B.II.b.1.a - Replacement manufacturing site for site B.II.b.2.c.2 - Change arrangements and quality Including batch control/testing B.II.b.1.b - Replacement manufacturing site for   |
|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

<div style=\"page-break-after: always\"></div>

| IB/0075/G   | This was an application for a group of variations.                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                          | 14/07/2022   | n/a   |
|-------------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|--------------|-------|
|             | B.I.b.2.c - Change in test procedure for AS or starting material/reagent/intermediate - Other changes to a test procedure for a reagent, which does not have a significant effect on the overall quality of the AS B.I.b.2.c - Change in test procedure for AS or starting material/reagent/intermediate - Other changes to a test procedure for a reagent, which does not have a significant effect on the overall quality of the AS B.I.b.2.c - Change in test procedure for AS or starting material/reagent/intermediate - Other changes to a test procedure for a reagent, which does not have a significant effect on the overall quality of the AS B.I.b.2.c - Change in test procedure for AS or starting material/reagent/intermediate - Other changes to a test procedure for a reagent, which does not have a significant effect on the overall quality of the AS B.I.b.2.c - Change in test procedure for AS or starting material/reagent/intermediate - Other changes to a test procedure for a reagent, which does not have a significant effect on the overall quality of the AS B.I.b.1.d - Change in the specification parameters and/or limits of an AS, starting material/intermediate/reagent - Deletion of a non- significant specification parameter (e.g. deletion of |              |       |

<div style=\"page-break-after: always\"></div>

|           | B.I.b.1.d - Change in the specification parameters and/or limits of an AS, starting material/intermediate/reagent - Deletion of a non- significant specification parameter (e.g. deletion of an obsolete parameter) B.I.b.1.b - Change in the specification parameters and/or limits of an AS, starting material/intermediate/reagent - Tightening of specification limits B.I.b.1.b - Change in the specification parameters and/or limits of an AS, starting material/intermediate/reagent - Tightening of specification limits B.I.b.1.b - Change in the specification parameters and/or limits of an AS, starting material/intermediate/reagent - Tightening of specification limits   |            |            |      |                                                                                                                                                                                                                                                    |
|-----------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|------------|------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| IG/1521   | B.II.b.1.a - Replacement or addition of a manufacturing site for the FP - Secondary packaging site                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                         | 23/06/2022 | n/a        |      |                                                                                                                                                                                                                                                    |
| IB/0074   | B.II.f.1.b.1 - Stability of FP - Extension of the shelf life of the finished product - As packaged for sale (supported by real time data)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                  | 22/03/2022 | 23/02/2023 | SmPC | PI is updated to reflect extension of the shelf life of the finished product Gilenya 0.25 mg Capsule, hard as packed for sale from 18 months to 24 months with storage condition `Do not store above 25 Â°C' for countries in Climatic Zone I & II. |
| IA/0073/G | This was an application for a group of variations. B.II.d.2.a - Change in test procedure for the finished product - Minor changes to an approved test                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                      | 31/01/2022 | n/a        |      |                                                                                                                                                                                                                                                    |

<div style=\"page-break-after: always\"></div>

|                    | procedure B.II.d.2.a - Change in test procedure for the finished product - Minor changes to an approved test procedure B.II.d.1.a - Change in the specification parameters and/or limits of the finished product - Tightening of specification limits B.II.d.2.a - Change in test procedure for the finished product - Minor changes to an approved test procedure B.II.d.1.a - Change in the specification parameters and/or limits of the finished product - Tightening of specification limits B.II.d.2.a - Change in test procedure for the finished product - Minor changes to an approved test procedure B.II.d.1.a - Change in the specification parameters and/or limits of the finished product - Tightening of   |            |            |                       |                                   |
|--------------------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|------------|-----------------------|-----------------------------------|
| PSUSA/1393/ 202102 | Periodic Safety Update EU Single assessment - fingolimod                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                   | 30/09/2021 | n/a        |                       | PRAC Recommendation - maintenance |
| IA/0072            | A.4 - Administrative change - Change in the name and/or address of a manufacturer or an ASMF holder or supplier of the AS, starting material, reagent or intermediate used in the manufacture of the AS or manufacturer of a novel excipient                                                                                                                                                                                                                                                                                                                                                                                                                                                                               | 09/09/2021 | n/a        |                       |                                   |
| II/0070/G          | This was an application for a group of variations. Submission of the non-interventional final study                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                        | 08/07/2021 | 27/01/2022 | SmPC, Annex II and PL |                                   |

<div style=\"page-break-after: always\"></div>

|         | report D2403 (long-term, prospective, multinational, parallel-cohort study monitoring safety in patients with multiple sclerosis newly started on fingolimod once daily or treated with another approved disease- modifying therapy). Submission of the non-interventional final study report D2406/D2409 (long-term, prospective, non- interventional, multinational, parallel-cohort study monitoring safety in patients with MS newly initiated on fingolimod once daily or treated with another approved disease-modifying therapy (including cardiac sub-study D2409)). Consequently, the Annex IID is updated to remove the obligation to perform the PASS D2409. The RMP v 19.1 has been agreed. In addition, the MAH took the opportunity to implement some minor editorial changes and to update the UK (Northern Ireland) local representative details in the PL. C.I.13 - Other variations not specifically covered elsewhere in this Annex which involve the submission of studies to the competent authority C.I.11.b - Introduction of, or change(s) to, the obligations and conditions of a marketing authorisation, including the RMP - Implementation of change(s) which require to be further substantiated   |            |     |
|---------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|-----|
| IA/0069 | B.II.e.6.b - Change in any part of the (primary) packaging material not in contact with the finished                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                            | 22/02/2021 | n/a |

<div style=\"page-break-after: always\"></div>

|                    | product formulation - Change that does not affect the product information                                                                                                                                                                    |            |            |                        |                                                                                                                                                                                                                                                                       |
|--------------------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|------------|------------------------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| IB/0068            | C.z - Safety, Efficacy, Pharmacovigilance changes - Other variation                                                                                                                                                                          | 07/01/2021 | 27/01/2022 | Annex II               |                                                                                                                                                                                                                                                                       |
| PSUSA/1393/ 202002 | Periodic Safety Update EU Single assessment - fingolimod                                                                                                                                                                                     | 15/10/2020 | 14/12/2020 | SmPC and PL            | Refer to Scientific conclusions and grounds recommending the variation to terms of the Marketing Authorisation(s)' for PSUSA/1393/202002.                                                                                                                             |
| IA/0067            | A.4 - Administrative change - Change in the name and/or address of a manufacturer or an ASMF holder or supplier of the AS, starting material, reagent or intermediate used in the manufacture of the AS or manufacturer of a novel excipient | 07/12/2020 | n/a        |                        |                                                                                                                                                                                                                                                                       |
| R/0063             | Renewal of the marketing authorisation.                                                                                                                                                                                                      | 17/09/2020 | 16/11/2020 | SmPC, Labelling and PL | Based on the review of data on quality, safety and efficacy, the CHMP considered that the benefit-risk balance of Gilenya in the approved indication remains favourable and therefore recommended the renewal of the marketing authorisation with unlimited validity. |
| IB/0065            | C.I.11.z - Introduction of, or change(s) to, the obligations and conditions of a marketing authorisation, including the RMP - Other variation                                                                                                | 07/08/2020 | 16/11/2020 | Annex II               |                                                                                                                                                                                                                                                                       |
| IB/0066            | B.II.b.3.z - Change in the manufacturing process of the finished or intermediate product - Other variation                                                                                                                                   | 31/07/2020 | n/a        |                        |                                                                                                                                                                                                                                                                       |
| IAIN/0064          | B.II.b.1.a - Replacement or addition of a manufacturing site for the FP - Secondary packaging site                                                                                                                                           | 15/07/2020 | n/a        |                        |                                                                                                                                                                                                                                                                       |

<div style=\"page-break-after: always\"></div>

| IA/0061   | B.I.c.1.z - Change in immediate packaging of the AS - Other variation                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                       | 17/04/2020   | n/a   |
|-----------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|--------------|-------|
| IA/0060/G | This was an application for a group of variations. B.III.1.b.2 - Submission of a new/updated or deletion of Ph. Eur. TSE Certificate of Suitability - New certificate for a starting material/reagent/intermediate/or excipient from a new or an already approved manufacturer B.III.1.b.2 - Submission of a new/updated or deletion of Ph. Eur. TSE Certificate of Suitability - New certificate for a starting material/reagent/intermediate/or excipient from a new or an already approved manufacturer B.III.1.b.2 - Submission of a new/updated or deletion of Ph. Eur. TSE Certificate of Suitability - New certificate for a starting material/reagent/intermediate/or excipient from a new or an already approved manufacturer B.III.1.b.2 - Submission of a new/updated or deletion of Ph. Eur. TSE Certificate of Suitability - New certificate for a starting material/reagent/intermediate/or excipient from a new or an already approved manufacturer B.III.1.b.2 - Submission of a new/updated or deletion of Ph. Eur. TSE Certificate of Suitability - New certificate for a starting material/reagent/intermediate/or excipient from a new or an already approved manufacturer B.III.1.b.3 - Submission of a new/updated or | 27/03/2020   | n/a   |

<div style=\"page-break-after: always\"></div>

<!-- image -->

| Updated certificate from manufacturer B.III.1.b.3 - Submission deletion of Ph. Eur. Updated certificate from manufacturer B.III.1.b.3 - Submission deletion of Ph. Eur. Updated certificate from manufacturer B.III.1.b.4 - Submission deletion of Ph. Eur. Deletion of certificates exist per material) B.III.1.b.4 - Submission deletion of Ph. Eur. Deletion of certificates exist per material) B.III.1.b.4 - Submission deletion of Ph. Eur. Deletion of certificates exist per material) B.III.1.b.4 - Submission deletion of Ph. Eur. Deletion of certificates exist per material) B.III.1.b.4 - Submission deletion of Ph. Eur. Deletion of certificates exist per material) B.III.1.b.4 - Submission   |
|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

<div style=\"page-break-after: always\"></div>

|                    | Deletion of certificates (in case multiple certificates exist per material) B.III.1.b.4 - Submission of a new/updated or deletion of Ph. Eur. TSE Certificate of Suitability - Deletion of certificates (in case multiple certificates exist per material)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                      |            |            |             |                                                                                                                                           |
|--------------------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|------------|-------------|-------------------------------------------------------------------------------------------------------------------------------------------|
| PSUSA/1393/ 201902 | Periodic Safety Update EU Single assessment - fingolimod                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                        | 17/10/2019 | 16/12/2019 | SmPC and PL | Refer to Scientific conclusions and grounds recommending the variation to terms of the Marketing Authorisation(s)' for PSUSA/1393/201902. |
| IAIN/0059/G        | This was an application for a group of variations. A.5.b - Administrative change - Change in the name and/or address of a manufacturer/importer of the finished product, including quality control sites (excluding manufacturer for batch release) A.5.b - Administrative change - Change in the name and/or address of a manufacturer/importer of the finished product, including quality control sites (excluding manufacturer for batch release) A.5.b - Administrative change - Change in the name and/or address of a manufacturer/importer of the finished product, including quality control sites (excluding manufacturer for batch release) A.7 - Administrative change - Deletion of manufacturing sites A.7 - Administrative change - Deletion of manufacturing sites B.II.b.1.a - Replacement or addition of a manufacturing site for the FP - Secondary packaging | 24/10/2019 | n/a        |             |                                                                                                                                           |

<div style=\"page-break-after: always\"></div>

| IB/0058/G   | This was an application for a group of variations. B.II.b.3.z - Change in the manufacturing process of the finished or intermediate product - Other variation B.II.b.3.z - Change in the manufacturing process of the finished or intermediate product - Other variation B.II.b.3.z - Change in the manufacturing process of the finished or intermediate product - Other variation                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                             | 16/09/2019   | n/a        |                       |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                 |
|-------------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|--------------|------------|-----------------------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| II/0053     | To update section 4.4 (subsection 'Return of disease activity (rebound)' and subsection 'Stopping therapy') to add information to prescribers on the timing of reported events and further recommendations on monitoring of patients, section 4.6 to add a warning for women stopping treatment for the purpose of becoming pregnant and for pregnant women and section 4.8 to add a new adverse reaction 'Severe exacerbation of disease after Gilenya discontinuation' with frequency 'Not known'. Additional information is included regarding the potential benefit of Gilenya use in pregnant women and women of child-bearing potential (WCBP) not using effective contraception regarding its reproductive toxicity in sections 4.3 to add contraindication regarding pregnant women and WCBP not using effective contraception, 4.4 to add a warning, with a cross reference to the contraindication and 4.6 to add information regarding the contraindication (the 2 fold increase risk of malformation and the malformations types; a | 25/07/2019   | 03/09/2019 | SmPC, Annex II and PL | The MAH provided a review of information from the published literature (Vermersch et al (2017)), including epidemiological evaluation, the Novartis safety database, and clinical studies (FREEDOMS/FTY720D2301 and FREEDOMS II/FTY720D2309) covering at least 3 months after treatment withdrawal to support a labelling update regarding rebound effect (in sections 4.4, 4.6 and 4.8). This has generally been observed within 12 weeks after stopping fingolimod, but has also been reported up to 24 weeks after fingolimod discontinuation recommending the patient monitoring if treatment discontinuation is deemed necessary. Furthermore, post marketing data was also provided to support changes related to the LEG 037 procedure concerning the increased risk of major congenital malformations and contraindication of Gilenya use in pregnant women and women of child-bearing potential, not using effective contraception regarding its reproductive toxicity. As a result SmPC sections 4.3, 4.4 and 4.6 have been updated to include contraindication regarding pregnant women and WCBP not using effective |

<div style=\"page-break-after: always\"></div>

|           | cross-reference to the educational materials and a reference that Gilenya must be stopped if a women becomes pregnant, medical advice should be given regarding the risk to the foetus and the need for ultrasonography examinations). The Package Leaflet is updated accordingly. The updated RMP version 16.1 has also been submitted to remove the 'PRIM' (Gilenya Pregnancy outcomes Intensive Monitoring) and to introduce amendments to the protocol of Study D2404 and update of the educational materials to reflect the contraindication (update of physician's checklist, rename the Patient / Parent / Caregiver card to a Patient / Parent / Caregiver guide with update of the key messages, addition of measures to prevent pregnancy and introduction of a new Pregnancy- specific patient reminder card). A DHPC and Communication plan was agreed. C.I.4 - Change(s) in the SPC, Labelling or PL due to new quality, preclinical, clinical or pharmacovigilance   |            |     | contraception.   |
|-----------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|-----|------------------|
| IG/1100   | A.7 - Administrative change - Deletion of manufacturing sites                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                      | 24/05/2019 | n/a |                  |
| IG/1099   | A.7 - Administrative change - Deletion of manufacturing sites                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                      | 24/05/2019 | n/a |                  |
| IB/0054/G | This was an application for a group of variations. B.II.b.3.z - Change in the manufacturing process of                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                             | 23/05/2019 | n/a |                  |

<div style=\"page-break-after: always\"></div>

|                    | the finished or intermediate product - Other variation B.II.b.3.z - Change in the manufacturing process of the finished or intermediate product - Other variation                                                                                                                             |            |            |                                  |                                                                                                                                           |
|--------------------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|------------|----------------------------------|-------------------------------------------------------------------------------------------------------------------------------------------|
| IB/0052            | C.I.z - Changes (Safety/Efficacy) of Human and Veterinary Medicinal Products - Other variation                                                                                                                                                                                                | 17/12/2018 | 03/09/2019 | SmPC, Annex II, Labelling and PL |                                                                                                                                           |
| PSUSA/1393/ 201802 | Periodic Safety Update EU Single assessment - fingolimod                                                                                                                                                                                                                                      | 20/09/2018 | 22/11/2018 | SmPC, Annex II and PL            | Refer to Scientific conclusions and grounds recommending the variation to terms of the Marketing Authorisation(s)' for PSUSA/1393/201802. |
| X/0044/G           | This was an application for a group of variations. Annex I_2.(c) Change or addition of a new strength/potency C.I.6.a - Change(s) to therapeutic indication(s) - Addition of a new therapeutic indication or modification of an approved one                                                  | 20/09/2018 | 22/11/2018 | SmPC, Annex II, Labelling and PL |                                                                                                                                           |
| IA/0051            | C.I.z - Changes (Safety/Efficacy) of Human and Veterinary Medicinal Products - Other variation                                                                                                                                                                                                | 02/07/2018 | 22/11/2018 | Annex II, Labelling and PL       |                                                                                                                                           |
| IA/0050/G          | This was an application for a group of variations. B.I.b.1.b - Change in the specification parameters and/or limits of an AS, starting material/intermediate/reagent - Tightening of specification limits B.I.b.1.c - Change in the specification parameters and/or limits of an AS, starting | 27/06/2018 | n/a        |                                  |                                                                                                                                           |

<div style=\"page-break-after: always\"></div>

<!-- image -->

|         | specification parameter to the specification with its corresponding test method B.I.b.1.c - Change in the specification parameters and/or limits of an AS, starting material/intermediate/reagent - Addition of a new specification parameter to the specification with its corresponding test method B.I.b.1.c - Change in the specification parameters and/or limits of an AS, starting material/intermediate/reagent - Addition of a new specification parameter to the specification with its corresponding test method B.I.b.1.d - Change in the specification parameters and/or limits of an AS, starting material/intermediate/reagent - Deletion of a non- significant specification parameter (e.g. deletion of an obsolete parameter) B.I.b.2.c - Change in test procedure for AS or starting material/reagent/intermediate - Other changes to a test procedure for a reagent, which does not have a significant effect on the overall quality of the AS B.I.b.2.c - Change in test procedure for AS or starting material/reagent/intermediate - Other changes to a test procedure for a reagent, which does not have a significant effect on the overall   |            |     |
|---------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|-----|
| II/0047 | Submission of the CSR for Study D2399 (part 1), a long-term safety and tolerability study of fingolimod 0.5 mg/day in approximately 5000 patients with relapsing multiple sclerosis; the RMP is updated                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                               | 17/05/2018 | n/a |

<div style=\"page-break-after: always\"></div>

|                    | (version 14.1) to reflect the completion of the study. C.I.13 - Other variations not specifically covered elsewhere in this Annex which involve the submission of studies to the competent authority                                                                                                                                                                                                                                                                                                           |            |            |                        |                                                                                                                                           |
|--------------------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|------------|------------------------|-------------------------------------------------------------------------------------------------------------------------------------------|
| T/0048             | Transfer of Marketing Authorisation                                                                                                                                                                                                                                                                                                                                                                                                                                                                            | 20/03/2018 | 23/04/2018 | SmPC, Labelling and PL |                                                                                                                                           |
| IB/0045            | C.I.z - Changes (Safety/Efficacy) of Human and Veterinary Medicinal Products - Other variation                                                                                                                                                                                                                                                                                                                                                                                                                 | 10/01/2018 | 23/04/2018 | SmPC and PL            |                                                                                                                                           |
| IA/0046            | B.II.b.3.a - Change in the manufacturing process of the finished or intermediate product - Minor change in the manufacturing process                                                                                                                                                                                                                                                                                                                                                                           | 18/12/2017 | n/a        |                        |                                                                                                                                           |
| PSUSA/1393/ 201702 | Periodic Safety Update EU Single assessment - fingolimod                                                                                                                                                                                                                                                                                                                                                                                                                                                       | 12/10/2017 | 08/12/2017 | SmPC and PL            | Refer to Scientific conclusions and grounds recommending the variation to terms of the Marketing Authorisation(s)' for PSUSA/1393/201702. |
| IB/0043/G          | This was an application for a group of variations. A.4 - Administrative change - Change in the name and/or address of a manufacturer or an ASMF holder or supplier of the AS, starting material, reagent or intermediate used in the manufacture of the AS or manufacturer of a novel excipient B.I.a.1.a - Change in the manufacturer of AS or of a starting material/reagent/intermediate for AS - The proposed manufacturer is part of the same pharmaceutical group as the currently approved manufacturer | 10/10/2017 | n/a        |                        |                                                                                                                                           |

<div style=\"page-break-after: always\"></div>

<!-- image -->

| B.I.a.1.z - Change in the starting material/reagent/intermediate variation B.I.a.1.z - Change in the starting material/reagent/intermediate variation B.I.a.2.a - Changes in the AS - Minor change of the AS B.I.a.3.b - Change in batch ranges) of AS or intermediate 10-fold B.I.a.4.c - Change to in-process applied during the manufacture of a non-significant in-process B.I.b.1.c - Change in the and/or limits of an AS, material/intermediate/reagent specification parameter corresponding test method B.I.b.1.c - Change in the and/or limits of an AS, material/intermediate/reagent specification parameter corresponding test method B.I.b.1.d - Change in the and/or limits of an AS, material/intermediate/reagent significant specification an obsolete parameter) B.I.b.1.d - Change in the   |
|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

<div style=\"page-break-after: always\"></div>

|         | material/intermediate/reagent - Deletion of a non- significant specification parameter (e.g. deletion of an obsolete parameter)                                                                                                                                                                                                                                                                                                                |            |            |      |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                   |
|---------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|------------|------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| II/0040 | Update of section 5.3 of the SmPC to include information about the dose correspondence between human and the species used for the preclinical tests of teratogenicity. RMP is updated (version 12.0). The MAH took the opportunity to make minor changes in sections 4.4, 4.5, 4.6 and 5.2 of the SmPC and also in Annex II. C.I.4 - Change(s) in the SPC, Labelling or PL due to new quality, preclinical, clinical or pharmacovigilance data | 18/05/2017 | 08/12/2017 | SmPC | Fingolimod was teratogenic in the rat when given at doses of 0.1 mg/kg or higher. Drug exposure in rats at this dose was similar to that in patients at the therapeutic dose (0.5 mg). The teratogenic potential in rabbits could not be fully assessed, however an increased embryo-foetal mortality was seen at doses of 1.5 mg/kg and higher, and a decrease in viable foetuses as well as foetal growth retardation was seen at 5 mg/kg. Drug exposure in rabbits at these doses was similar to that in patients. Before initiation of treatment in women of childbearing potential, a negative pregnancy test result needs to be available and counselling should be provided regarding the potential for serious risk to the foetus and the need for effective contraception during treatment with Gilenya. |
| II/0039 | Update of sections 4.4 and 4.8 of the SmPC to add an approximate time of onset for multifocal leukoencephalopathy (PML) and for cryptococcal meningitis (CM) and to remove the term isolated from \"isolated cases of CM\". C.I.4 - Change(s) in the SPC, Labelling or PL due to new quality, preclinical, clinical or pharmacovigilance data                                                                                                    | 26/01/2017 | 08/12/2017 | SmPC | Section 4.4 of the SmPC has been amended to add the following detail to the existing warning on cryptococcal meningitis: 'Cases of cryptococcal meningitis (a fungal infection) have been reported in the post-marketing setting after approximately 2 3 years of treatment, although an exact relationship with the duration of treatment is unknown.' In addition, the existing warning on leukoencephalopathy (PML) has been updated with the following: 'Cases of PML have occurred after approximately 2 3 years of monotherapy treatment without previous exposure to natalizumab, although an exact relationship with the duration of treatment is unknown. Additional PML cases                                                                                                                           |

<div style=\"page-break-after: always\"></div>

|                    |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                             |            |            |             | have occurred in patients who had been treated previously with natalizumab, which has a known association with PML.'                                                                                                                                                                                                                                                                                                                                                                                                                                                                                  |
|--------------------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|------------|-------------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| PSUSA/1393/ 201602 | Periodic Safety Update EU Single assessment - fingolimod                                                                                                                                                                                                                                                                                                                                                                                                                                    | 13/10/2016 | 08/12/2016 | SmPC and PL | Refer to Scientific conclusions and grounds recommending the variation to terms of the Marketing Authorisation(s)' for PSUSA/1393/201602.                                                                                                                                                                                                                                                                                                                                                                                                                                                             |
| IG/0712            | A.5.b - Administrative change - Change in the name and/or address of a manufacturer/importer of the finished product, including quality control sites (excluding manufacturer for batch release)                                                                                                                                                                                                                                                                                            | 03/08/2016 | n/a        |             |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                       |
| II/0037            | Update of sections 4.4 and 4.8 of the SmPC in order to amend the safety information to include additional warning and guidance on Progressive Multifocal Leukoencephalopathy (PML). The Package Leaflet is updated accordingly. In addition, the MAH took this opportunity to make corrections in the labelling. A new RMP version 11.0 was agreed during this procedure. C.I.4 - Change(s) in the SPC, Labelling or PL due to new quality, preclinical, clinical or pharmacovigilance data | 17/12/2015 | 25/01/2016 | SmPC and PL | Case of Progressive Multifocal Leukoencephalopathy (PML) occurring in post marketing patients under Gilenya treatment. PML typically only occurs in patients who are immunocompromised. Before initiating treatment with fingolimod, a baseline Magnetic Resonance Imaging (MRI) should be available (usually within 3 months) as a reference. During routine MRI, physicians should pay attention to PML suggestive lesions. In case of PML is suspected, MRI should be performed immediately for diagnostic purposes and treatment with fingolimod should be suspended until PML has been excluded. |
| R/0036             | Renewal of the marketing authorisation.                                                                                                                                                                                                                                                                                                                                                                                                                                                     | 24/09/2015 | 23/11/2015 |             | Based on the review of the available information the CHMP is of the opinion that the quality, the safety and the efficacy of this medicinal product continues to be adequately and sufficiently demonstrated and therefore considers that the benefit/risk profile of Gilenya continues to be favourable. However, since the first launch of the product, the following safety issues have been identified with Gilenya:                                                                                                                                                                              |

<div style=\"page-break-after: always\"></div>

|                    |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                    |            |            |             | bradyarrhythmia, PRES, lymphoma, periodicity of complete blood count (CBC), HPS, hypersensitivity following a bullous erythema multiform , PML, cryptococcal infections, opportunistic infections, BCC, urticarial, angioedema, Kaposi sarcoma, Tumefactive relapses, T-wave inversion, peripheral oedema, retinal disorders, RCVS, fatal cases including unexplained death and safety concerns after treatment by DMTs. These issues have led to updates of the SmPC and updates of the Pharmacovigilance Plan. Therefore, based upon the safety profile of Gilenya, which requires the submission of yearly PSURs, the CHMP was of the opinion that an additional five-year renewal on the basis of pharmacovigilance grounds was required.   |
|--------------------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|------------|-------------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| PSUSA/1393/ 201502 | Periodic Safety Update EU Single assessment - fingolimod                                                                                                                                                                                                                                                                                                                                                                                                                                                                                           | 24/09/2015 | 19/11/2015 | SmPC and PL | Refer to Scientific conclusions and grounds recommending the variation to terms of the Marketing Authorisation(s)' for PSUSA/1393/201502.                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                       |
| II/0034            | Extension of indication was amended to: Patients with highly active disease despite a full and adequate course of treatment with at least one disease modifying therapy. As a consequence, section 4.1 of the SmPC is updated. In addition, the applicant took the opportunity to relocate documents from section 5.3.5.1 to 5.3.5.2.' The variation proposed amendments to the Summary of Product Characteristics. C.I.6.a - Change(s) to therapeutic indication(s) - Addition of a new therapeutic indication or modification of an approved one | 24/09/2015 | 28/10/2015 | SmPC        | Please refer to scientific discussion in the published EPAR.                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                    |

<div style=\"page-break-after: always\"></div>

| II/0032   | Update of section 4.4 of the SmPC to include precautionary statements on cryptococcal meningitis and of section 4.8 of the SmPC to reflect cryptococcal infections, including isolated cases of cryptococcal meningitis. In addition, the Marketing authorisation holder took the opportunity to make a minor editorial change in section 4.5 of the SmPC to align with section 4.4 of the SmPC. The updated RMP version 9.0 has been submitted. C.I.4 - Change(s) in the SPC, Labelling or PL due to new quality, preclinical, clinical or pharmacovigilance data                       | 21/05/2015   | 03/07/2015   | SmPC and PL   | Isolated cases of cryptococcal meningitis (a fungal infection) have been reported in the post-marketing setting. Patients with symptoms and signs consistent with cryptococcal meningitis (e.g. headache accompanied by mental changes such as confusion, hallucinations, and/or personality changes) should undergo prompt diagnostic evaluation. If cryptococcal meningitis is diagnosed, fingolimod should be suspended and appropriate treatment should be initiated. A multidisciplinary consultation (i.e. infectious disease specialist) should be undertaken if re- initiation of fingolimod is warranted.   |
|-----------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|--------------|--------------|---------------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| IB/0033/G | This was an application for a group of variations. B.I.a.2.a - Changes in the manufacturing process of the AS - Minor change in the manufacturing process of the AS B.I.b.1.c - Change in the specification parameters and/or limits of an AS, starting material/intermediate/reagent - Addition of a new specification parameter to the specification with its corresponding test method B.I.b.1.a - Change in the specification parameters and/or limits of an AS, starting material/intermediate/reagent - Tightening of specification limits for medicinal products subject to OCABR | 18/05/2015   | n/a          |               |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                      |

<div style=\"page-break-after: always\"></div>

| IAIN/0031   | A.1 - Administrative change - Change in the name and/or address of the MAH                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                | 02/03/2015   | 03/07/2015   | SmPC, Labelling and PL   |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                     |
|-------------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|--------------|--------------|--------------------------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| IG/0484/G   | This was an application for a group of variations. A.7 - Administrative change - Deletion of manufacturing sites B.II.b.1.a - Replacement or addition of a manufacturing site for the FP - Secondary packaging site                                                                                                                                                                                                                                                                                                                                                                                       | 12/11/2014   | n/a          |                          |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                     |
| PSUV/0029   | Periodic Safety Update                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                    | 09/10/2014   | n/a          |                          | PRAC Recommendation - maintenance                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                   |
| II/0026/G   | This was an application for a group of variations. Group of variations consisting of an update of sections 5.1 and 5.2 of the Summary of Product Characteristics to reflect additional data regarding the mechanism of action of fingolimod and two clinical studies regarding penetration of fingolimod in the CNS and its distribution in male semen, respectively. C.I.4 - Change(s) in the SPC, Labelling or PL due to new quality, preclinical, clinical or pharmacovigilance data C.I.4 - Change(s) in the SPC, Labelling or PL due to new quality, preclinical, clinical or pharmacovigilance data | 24/07/2014   | 03/07/2015   | SmPC                     | After the review of the submitted data, the CHMP recommended additional information related to the mechanism of action (ie redistribution of lymphocytes) and the distribution of fingolimod into the brain and male semen, respectively, in the SmPC, as follows: - Mechanism of action: Animal studies have shown that the redistribution of lymphocytes reduces the infiltration of pathogenic lymphocytes, including pro-inflammatory Th17 cells, into the CNS. - Distribution: A study in four healthy subjects who received a single intravenous dose of a radioiodolabelled analogue of fingolimod demonstrated that fingolimod penetrates into the brain. In a study in 13 male multiple sclerosis patients who received Gilenya 0.5 mg/day, the mean amount of fingolimod (and fingolimod phosphate) in seminal ejaculate, at steady-state, was approximately 10,000 times lower than the oral dose administered (0.5 mg). |

<div style=\"page-break-after: always\"></div>

| PSUV/0027   | Periodic Safety Update                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                      | 25/04/2014   | 19/06/2014   | SmPC and PL            | Please refer to the scientific conclusions and grounds recommending the variation to the terms of the marketing authorisation Gilenya EMEA/H/C/002202/PSUV/0027.                                                                                                                                                                                                                                                                                                                                                  |
|-------------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|--------------|--------------|------------------------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| II/0021     | Modification of the indication (section 4.1) of Gilenya to extend the patient population to patients with high disease activity despite treatment with at least one disease modifying therapy (DMT). Consequential changes were made in section 4.4 of the SmPC to include safety information relevant to switching from other immunosuppressive or immunomodulatory therapies to Gilenya. The Package Leaflet has been amended accordingly. C.I.6.a - Change(s) to therapeutic indication(s) - Addition of a new therapeutic indication or | 25/04/2014   | 23/05/2014   | SmPC and PL            | Please refer to the scientific discussion Gilenya- H-002202- II-0021-AR.                                                                                                                                                                                                                                                                                                                                                                                                                                          |
| IB/0028     | B.II.e.5.a.2 - Change in pack size of the finished product - Change in the number of units (e.g. tablets, ampoules, etc.) in a pack - Change outside the range of the currently approved pack sizes                                                                                                                                                                                                                                                                                                                                         | 28/03/2014   | 23/05/2014   | SmPC, Labelling and PL |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                   |
| II/0025     | Update of section 5.2 of the Summary of Product Characteristics (SmPC) to amend the information related to the enzymes involved in the metabolic pathway of fingolimod. Section 4.5 is also updated to relocate the information related to potent inhibitors of transporter proteins under the related sub- heading. C.I.4 - Change(s) in the SPC, Labelling or PL due to                                                                                                                                                                   | 20/03/2014   | 23/05/2014   | SmPC                   | After the review of the MAH updated analysis of the available data regarding fingolimod metabolism, the CHMP concluded that no further data were provided that could exclude CYP3A4 involvement in fingolimod metabolism and therefore support the changes to the SmPC proposed initially by the MAH (i.e. deletion of the reference to CYP3A4 as an enzyme involved in the metabolic pathway of fingolimod and deletion of the cautionary statement related to the interaction with CYP3A4 inhibitors). The CHMP |

<div style=\"page-break-after: always\"></div>

|         | new quality, preclinical, clinical or pharmacovigilance data                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                            |            |            |                       | however recommended to reflect in the SmPC on the possible involvement of CYP isoenzymes other than CYP4F2 in fingolimod metabolism. Based on this assessment, the MAH did not pursue their initial proposed SmPC changes and agreed with the CHMP recommendations.                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                           |
|---------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|------------|-----------------------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| II/0024 | Update of sections 4.4 and 4.8 of the Summary of Product Characteristics (SmPC) regarding the adverse drug reactions (ADRs) based on pooled analysis of study D2301 and D2309 and latest integrated summary of safety update (ISS, 2012). Additional information is included regarding concomitant use of corticosteroid and posterior reversible encephalopathy syndrome (PRES) in section 4.4. The warning regarding varicella zoster virus (VZV) is updated to ascertain appropriate assessment of patient immunity to VZV prior to treatment. Section 4.2 was updated regarding signs of treatment related abnormalities present prior to switching therapy to Gilenya and the introductory efficacy/safety paragraph of section 5.1 was complemented by mentioning the third study completed after authorisation. Annex II and Sections 2 and 4 of the Package Leaflet were amended accordingly. C.I.4 - Change(s) in the SPC, Labelling or PL due to new quality, preclinical, clinical or pharmacovigilance data | 20/03/2014 | 23/05/2014 | SmPC, Annex II and PL | After review of the latest MAH safety analyses, the CHMP recommended the following main safety changes: - Neutropenia was replaced by cytopenia regarding the signs of relevant treatment related abnormalities when switching directly therapy to Gilenya. - Some ADRs were grouped (hepatic enzymes increases) and some frequencies were updated: hepatic enzyme increases, sinusitis, macular oedema, atrioventricular blocks and reduction in values for forced expiratory volume. This resulted in changes from common to very common adverse reactions (ADRs) for hepatic enzyme increases and sinusitis. - The overall rate of infections was updated. Herpes infection was added as a more common lower respiratory tract infection seen in Gilenya treated patients but observed at a lesser extent than bronchitis. The terms 'influenza viral infection' and 'tinea infections' were replaced by 'influenza' and 'tinea versicolor', respectively, as considered as a more accurate description of these ADRs. - The following ADRs were deleted: gastroenteritis, paraesthesia, eye pain and weight decreased. - PRES was included as a warning with physicians advised to stop Gilenya treatment if PRES is suspected. - The existing warnings to ascertain appropriate assessment of patient immunity to VZV prior to treatment |

<div style=\"page-break-after: always\"></div>

|           |                                                                                                                                                                                                                                                                                                                                                                                                                                        |            |            |                       | and on the concomitant use of corticosteroids were strengthened.                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                      |
|-----------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|------------|-----------------------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| PSUV/0023 | Periodic Safety Update                                                                                                                                                                                                                                                                                                                                                                                                                 | 24/10/2013 | 18/12/2013 | SmPC and PL           | Refer to Scientific conclusions and grounds recommending the variation to terms of the Marketing Authorisation for PSUV/0023.                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                         |
| II/0020   | Update of section 4.8 of the SmPC to add information on Haemophagocytic syndrome (HPS) following 2 case reports with Gilenya and as per the PRAC/CHMP request. C.I.z - Changes (Safety/Efficacy) of Human and Veterinary Medicinal Products - Other variation                                                                                                                                                                          | 24/10/2013 | 25/11/2013 | SmPC                  | Following a safety signal regarding the occurrence of 2 fatal cases of haemophagocytic syndrome with fingolimod, the PRAC/CHMP recommended an update of section 4.8 of the SmPC to reflect this information as well as to issue a Direct Healthcare Professional Communication (DHPC) with the aim of raising awareness on this risk and communicate about the difficulties of diagnosing HPS and the risk of a worse outcome when the diagnosis is delayed. Section 4.8 was updated as follows: - Very rare cases of haemophagocytic syndrome (HPS) with fatal outcome have been reported in patients treated with fingolimod in the context of an infection. HPS is a rare condition that has been described in association with infections, immunosupression and a variety of autoimmune diseases. |
| II/0019   | Update of section 4.4 of the Summary of Product Characteristics (SmPC) to specify the periodicity of complete blood count (CBC) following assessment of the responses to the CHMP conclusions on the first PSUR (PSU 017.2). In addition, update of the Product Information in accordance with the latest QRD template (version 9) including addition of the black symbol and explanatory statements related to additional monitoring. | 24/10/2013 | 25/11/2013 | SmPC, Annex II and PL | Following their assessment of PSUR 1 for Gilenya, the CHMP requested the MAH to review all serious cases reporting leucopenia and lymphopenia with at least important information such as time to onset and outcomes. Incidence of infections in clinical trials was found greater in groups of patients with a nadir lymphocyte count <0.2x109/L than in group 0.2-0.4x109/L and >0.4x109/L. In post-marketing, the lymphocytes counts were unknown for a significant number of cases so a correlation between infections and lymphocyte count could not be excluded.                                                                                                                                                                                                                                |

<div style=\"page-break-after: always\"></div>

|         | C.I.3.b - Implementation of change(s) requested following the assessment of an USR, class labelling, a PSUR, RMP, FUM/SO, data submitted under Article 45/46, or amendments to reflect a Core SPC - Change(s) with new additional data submitted by the MAH                                                                                                                                                                                                                                                                                                                                                  |            |            |      | Subsequently to these findings and taking also into account the data from last PSUR regarding fatal cases related to infections, the CHMP considered relevant to specify a periodicity for the complete blood count (CBC) in the SmPC. An update of the existing warning was made recommending assessment of CBC at month 3 and at least yearly thereafter.                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                   |
|---------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|------------|------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| II/0015 | Update of the Summary of Product Characteristics (SmPC) regarding the existing warning on bradyarrhythmia (section 4.4) and the occurrence of lymphoma (section 4.8), following assessment of the second PSUR. In addition, section 4.8 has been updated accordingly and hypotension has been added as an associated symptom of bradyarrhythmia. C.I.3.b - Implementation of change(s) requested following the assessment of an USR, class labelling, a PSUR, RMP, FUM/SO, data submitted under Article 45/46, or amendments to reflect a Core SPC - Change(s) with new additional data submitted by the MAH | 25/04/2013 | 25/11/2013 | SmPC | Following their assessment of PSUR 2 for Gilenya, the CHMP requested the MAH to review available data regarding the bradyarrhythmia effect of fingolimod and the occurrence of lymphoma. Subsequently to assessment of the presented analyses, the Product information has been updated to include the following concepts: - Section 4.4: after the first dose, the decline in heart rate starts within one hour, and is maximal within 6 hours. This post-dose effect persists over the following days, although usually to a milder extent, and usually abates over the next weeks. With continued administration, the average heart rate returns towards baseline within one month. However individual patients may not return to baseline heart rate by the end of the first month. - Section 4.8: there have been cases of lymphoma of different varieties, in both clinical studies and the post- marketing setting, including a fatal case of Epstein-Barr virus (EBV) positive B-cell lymphoma. The incidence of lymphoma (B-cell and T-cell) cases was higher in clinical trials than expected in the general population. In addition, section 4.8 has been updated to be in line with section 4.4 regarding the information on the bradyarrhythmia effect and to include hypotension as an associated symptom as follows: bradycardia was generally |

<div style=\"page-break-after: always\"></div>

|           |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                         |            |            |                   | asymptomatic but some patients experienced mild to moderate symptoms, including hypotension, dizziness, fatigue and/or palpitations, which resolved within the first 24 hours after treatment initiation.                                                                                     |
|-----------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|------------|-------------------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| IG/0296/G | This was an application for a group of variations. B.III.1.b.2 - Submission of a new or updated Ph. Eur. TSE Certificate of suitability - New certificate for a starting material/reagent/intermediate/or excipient from a new or an already approved manufacturer B.III.1.b.3 - Submission of a new or updated Ph. Eur. TSE Certificate of suitability - Updated certificate                                                                                                                                                                                                                                                           | 24/04/2013 | n/a        |                   |                                                                                                                                                                                                                                                                                               |
| II/0012/G | This was an application for a group of variations. Group of variations consisting of: 1) update of section 5.1 of the SmPC to include efficacy results of D2301E1 following assessment of FUM 7; 2) update of section 5.1 of the SmPC to include efficacy results of D2302E1 following assessment of FUM 8 and 3) update of section 5.1 of the SmPC to include efficacy results of D2309 following assessment of FUM 9. Annex II was also updated in accordance with the latest template. C.I.z - Changes (Safety/Efficacy) of Human and Veterinary Medicinal Products - Other variation C.I.z - Changes (Safety/Efficacy) of Human and | 21/02/2013 | 25/11/2013 | SmPC and Annex II | Based on the review of the submitted studies, the CHMP considered that their results are relevant to the benefit-risk profile of Gilenya and confirm its efficacy in the approved indication. The CHMP therefore accepted to include a description of the results in section 5.1 of the SmPC. |

<div style=\"page-break-after: always\"></div>

|         | Veterinary Medicinal Products - Other variation                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                               |            |            |                                  |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                          |
|---------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|------------|----------------------------------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| IG/0248 | C.I.z - Changes (Safety/Efficacy) of Human and Veterinary Medicinal Products - Other variation                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                | 17/12/2012 | n/a        |                                  |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                          |
| II/0013 | Update of section 4.4 of the SmPC related to monitoring of bradyarrhyhthmia to include a recommendation for the same first dose monitoring in specific situations when treatment is re-initiated after it was interrupted (reference is also made in section 4.2) and to recommend repeated first dose monitoring for the second dose in patients requiring pharmacological intervention after the first dose. Annex II and the Package Leaflet have been amended accordingly. Changes to the Product Information were also made in accordance with the latest QRD templates and the contact details of the local representative in Malta was updated. C.I.4 - Variations related to significant modifications of the SPC due in particular to new quality, pre- clinical, clinical or pharmacovigilance data | 13/12/2012 | 25/11/2013 | SmPC, Annex II, Labelling and PL | Based on the SmPC recommendation, all patients starting treatment with Gilenya should have their heart activity monitored before receiving the first dose of the medicine and continuously for at least six hours thereafter as some patients may develop heart problems such as bradycardia (a slow heart rate) or atrioventricular block (a problem with the conduction of electricity in the heart). The SmPC of Gilenya also recommends that this first dose monitoring be repeated if a patient, who was treated for more than 1 month with Gilenya and stopped taking it for two weeks or more, re-starts treatment. The timeframe of Gilenya therapy interruption has been investigated by the MAH using pharmacokinetics, pharmacokinetic/pharmacodynamic models and titration data to better define when such monitoring should be considered. Based on these data, the CHMP recommended to extend the current advice for heart activity monitoring in case of re-initiation of treatment to the following situations: 1) treatment is interrupted for one day or more during the first 2 weeks of treatment, 2) treatment is interrupted for more than 7 days during weeks 3 and 4 of treatment. In addition, such monitoring should be repeated for the second dose in patients requiring pharmacological intervention during the first dose. |
| II/0010 | Update of section 4.8 of the SmPC in relation to posterior reversible encephalopathy syndrome                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                 | 18/10/2012 | 22/11/2012 | SmPC and PL                      | On the basis of the data submitted, the CHMP considered that this present applicant fulfilled the request for updating                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                   |

<div style=\"page-break-after: always\"></div>

|           | (PRES) following assessment of the first European PSUR. Section 4 of the Package Leaflet (PL) has been amended accordingly. C.I.3.b - Implementation of change(s) requested following the assessment of an USR, class labelling, a PSUR, RMP, FUM/SO, data submitted under Article 45/46, or amendments to reflect a Core SPC - Change(s) with new additional data submitted by the MAH   |            |            |                        | the Product Information to include that PRES were also observed with the 0.5 mg dose used in the approved indication. The following information has been reflected in the Product Information: - Section 4.8: In clinical studies, rare events involving the nervous system occurred in patients treated with fingolimod at higher doses (1.25 or 5.0 mg) including ischemic and haemorrhagic strokes, posterior reversible encephalopathy syndrome and neurological atypical disorders, such as acute disseminated encephalomyelitis (ADEM)-like events. Rare cases of posterior reversible encephalopathy syndrome have also been reported at doses of 0.5 mg in both the clinical and the post-marketing setting. - Section 4: Rare: A condition called posterior reversible encephalopathy syndrome (PRES). Symptoms may be   |
|-----------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|------------|------------------------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| IB/0014   | B.II.f.1.d - Stability of FP - Change in storage conditions of the finished product or the diluted/reconstituted product                                                                                                                                                                                                                                                                  | 07/11/2012 | 25/11/2013 | SmPC, Labelling and PL |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                   |
| IG/0209/G | This was an application for a group of variations. C.I.9.b - Changes to an existing pharmacovigilance system as described in the DDPS - Change in the contact details of the QPPV C.I.9.h - Changes to an existing pharmacovigilance system as described in the DDPS - Other change(s) to the DDPS that does not impact on the operation of                                               | 17/08/2012 | n/a        |                        |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                   |

<div style=\"page-break-after: always\"></div>

|                    |                                                                                                                                                                                                                                                                                                                                                                                                                                  | 19/04/2012   | 18/06/2012   | SmPC, Annex II and PL   | Please refer to the assessment report: EMEA/H/C/2202/A- 20/008   |
|--------------------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|--------------|--------------|-------------------------|------------------------------------------------------------------|
| A20/0008 IG/0148/G | Pursuant to Article 20 of Regulation (EC) No 726/2004, the European Commission requested on 18 January 2012, the opinion of the CHMP on measures necessary to ensure the safe use of the above mentioned medicinal product further to the CHMP review on cardiovascular adverse events following administration of the first dose and its impact on the risk-benefit balance. This was an application for a group of variations. | 22/02/2012   | n/a          |                         |                                                                  |
| N/0007             | The Marketing Authorisation Holder (MAH) took the opportunity to update 'Liver function tests' in section 2 of the Package Leaflet. Minor change in labelling or package leaflet not connected with the SPC (Art. 61.3 Notification)                                                                                                                                                                                             | 03/02/2012   | 18/06/2012   | PL                      |                                                                  |

<div style=\"page-break-after: always\"></div>

| IA/0006/G   | This was an application for a group of variations.                                                                                                                                                                                                                                                                                                                                                                                                                                                    | 15/12/2011   | n/a        |                   |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                |
|-------------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|--------------|------------|-------------------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| II/0002     | Update of sections 4.4 and 4.8 of the SmPC to revise the time of occurrence of liver enzymes elevations and related recommendation on monitoring. Annex II was consequently updated in accordance with the latest QRD templates and an editorial change was made to the address of the manufacturer for batch release regarding the city name. C.I.4 - Variations related to significant modifications of the SPC due in particular to new quality, pre- clinical, clinical or pharmacovigilance data | 20/10/2011   | 14/12/2011 | SmPC and Annex II | On the basis of the submitted data, the CHMP recommended to revise the time of occurrence of liver enzymes elevations and related recommendation on monitoring. The relevant text resulting from this variation is as follows: Section 4.4: Recent (i.e. within last 6 months) transaminase and bilirubin levels should be available before initiation of treatment with Gilenya. In the absence of clinical symptoms, liver transaminases should be monitored at Months 1, 3, 6 ,9 and 12 on therapy and periodically thereafter. If liver transaminases rise above 5 times the ULN, more frequent monitoring should be instituted, including serum bilirubin and alkaline phosphatase (ALP) measurement. With repeated confirmation of liver transaminases above 5 times the ULN, treatment with Gilenya should be interrupted and only re-commenced once liver transaminase values have normalised. Sections 4.4 and 4.8: In clinical studies, transaminase elevations occurred at any time during treatment although the majority occurred |

<div style=\"page-break-after: always\"></div>

|           |                                                                                                                                                                                                                                                                                                                                                                                                                              |            |            |                    | within the first 12 months.   |
|-----------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|------------|--------------------|-------------------------------|
| IG/0113/G | This was an application for a group of variations. B.III.1.b.3 - Submission of a new or updated Ph. Eur. TSE Certificate of suitability - Updated certificate from an already approved manufacturer B.III.1.b.3 - Submission of a new or updated Ph. Eur. TSE Certificate of suitability - Updated certificate from an already approved manufacturer                                                                         | 11/11/2011 | n/a        |                    |                               |
| IG/0109   | C.I.9.i - Changes to an existing pharmacovigilance system as described in the DDPS - Change(s) to a DDPS following the assessment of the same DDPS in relation to another medicinal product of the same MAH                                                                                                                                                                                                                  | 30/09/2011 | n/a        | Annex II           |                               |
| IA/0001/G | This was an application for a group of variations. B.II.e.6.a - Change in any part of the (primary) packaging material not in contact with the finished product formulation - Change that affects the product information B.II.e.5.a.1 - Change in pack size of the finished product - Change in the number of units (e.g. tablets, ampoules, etc.) in a pack - Change within the range of the currently approved pack sizes | 28/04/2011 | 28/04/2011 | SmPC and Labelling |                               |